CARTITUDE-6 asks whether a single CAR-T infusion can replace the stem cell transplant that has anchored myeloma treatment for thirty years, when both follow the same four-drug induction.
CARTITUDE-6 (also EMN28) is a phase 3 trial of 759 transplant-eligible patients with newly diagnosed multiple myeloma. All receive DVRd induction; one arm then proceeds to high-dose melphalan and autologous stem cell transplant with DVRd consolidation, the other to a single infusion of the BCMA-directed CAR-T ciltacabtagene autoleucel, and both go on to lenalidomide maintenance. The primary endpoints are progression-free survival and sustained minimal residual disease negativity.
The trial is running and has not reported. Its answer will decide whether transplant remains the standard consolidation for fit patients or gives way to cellular therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Bortezomib, Dexamethasone and the tag subtype-trials.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson and the tag subtype-trials.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Bortezomib, Lenalidomide, Dexamethasone and the tag subtype-trials.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Bortezomib, Lenalidomide, Dexamethasone and the tag subtype-trials.
Shares Daratumumab, Johnson & Johnson, Monoclonal antibodies, Multiple myeloma and the tag subtype-trials.
Shares Ciltacabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide.
Shares Johnson & Johnson and the tag subtype-trials.
Shares Johnson & Johnson and the tag subtype-trials.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/